

THE MECHANISTIC INSIGHTS OF SITAGLIPTIN IN AMELIORATING COLORECTAL CARCINOMA

SAYONI NAG

Sitagliptin is a well known drug, widely used in the market against Type II diabetes to inhibit DPP4 and has shown good results in human with a few adverse effects. This review focuses on the efficacy of sitagliptin to inhibit colorectal cancer. It has been seen that Sitagliptin prevents the development of acryptic foci, and growth of tumor cells by reducing ROS levels, lowering IL6 expression, enhancing CD8+T cell infiltration and by modulating CD24, SOX4 and β catenin levels.
